
    
      This is an open-label, multinational, multicenter, randomized, comparative efficacy and
      safety study in previously untreated patients with carcinoma of unknown primary. Patients
      meeting inclusion and exclusion criteria will be randomized to treatment in Arm A (BelCaP) or
      Arm B (CaP).
    
  